NCT02871427 - Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 20, 2016

Primary Completion Date

January 17, 2019

Study Completion Date

January 17, 2019

Conditions

Lewy Body DementiaDementia With Lewy BodiesParkinson's Disease DementiaVisual HallucinationsREM Sleep Behavior Disorder

Interventions

DRUG

Nelotanserin

Once Daily, Oral, at 20, 40, 60, or 80 mg dose

Trial Locations (19)

27514

US101, Chapel Hill

32174

US152, Ormond Beach

32751

US180, Maitland

32806

US113, Orlando

33486

US114, Boca Raton

34471

US154, Ocala

35294

US120, Birmingham

38163

US128, Memphis

43210

US105, Columbus

44195

US104, Cleveland

45229

US111, Cincinnati

46202

US107, Indianapolis

55905

US103, Rochester

58103

US147, Fargo

66214

US132, Lenexa

68526

US129, Lincoln

77205

US143, Little Rock

78229

US131, San Antonio

02865

US173, Lincoln